<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344135</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 11-3-004</org_study_id>
    <nct_id>NCT01344135</nct_id>
  </id_info>
  <brief_title>Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy</brief_title>
  <acronym>NUTRAIN</acronym>
  <official_title>Cost Effectiveness Analysis and Clinical Outcome of Nutritional Rehabilitation on Physical Functioning and Cardiometabolic Risk Profile in COPD Patients With Muscle Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Netherlands Asthma Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study in clinically stable Chronic Obstructive Pulmonary Disease (COPD) patients with&#xD;
      muscle atrophy:&#xD;
&#xD;
        1. The short-term effects of 4 months exercise training including nutritional&#xD;
           supplementation versus exercise training alone on physical functioning (skeletal muscle&#xD;
           strength and exercise capacity) and body composition.&#xD;
&#xD;
        2. The long-term effects of 4 months of exercise training and nutritional supplementation&#xD;
           followed by 8 months of nutritional counseling (with supplementation on advice) and&#xD;
           feedback on physical activity level versus 4 months of exercise training and 8 months&#xD;
           with feedback on physical activity level alone on physical functioning, body composition&#xD;
           and cardiometabolic risk profile;&#xD;
&#xD;
        3. The cost-effectiveness of exercise rehabilitation and nutritional intervention versus&#xD;
           exercise rehabilitation alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale. Recent guidelines state that pulmonary rehabilitation should be part of integrated&#xD;
      care of patients with COPD and not limited to end stage disease. The investigators&#xD;
      hypothesize that clinically stable COPD patients muscle atrophy, irrespective of the severity&#xD;
      of airflow obstruction, show more pronounced long-term improvement in physical functioning&#xD;
      and cardiometabolic risk profile after a rehabilitation programme including nutritional&#xD;
      intervention (supplementation and counseling) than after a pulmonary rehabilitation programme&#xD;
      without nutritional intervention, at acceptable costs. Nutritional supplementation focuses on&#xD;
      enhancing the efficacy of the exercise training. Nutritional counseling aims at maintaining&#xD;
      energy balance and modulating cardiovascular disease risk.&#xD;
&#xD;
      Study design. The research aims will be addressed in a multi-centre, randomized, clinical&#xD;
      trial.&#xD;
&#xD;
      Phase A, Rehabilitation (4 months):&#xD;
&#xD;
        -  Group 1: Supervised exercise training and 3 placebo nutritional supplements daily&#xD;
&#xD;
        -  Group 2: Supervised exercise training and 3 nutritional supplements daily&#xD;
&#xD;
      Phase B, Maintenance (8 months):&#xD;
&#xD;
        -  Group 1: Exercise counseling (2x)&#xD;
&#xD;
        -  Group 2: Exercise counseling (2x), nutritional counseling (5x) (and 1 nutritional&#xD;
           supplement a day on indication)&#xD;
&#xD;
      Phase C, Follow-up (3 months):&#xD;
&#xD;
        -  Group 1: no intervention&#xD;
&#xD;
        -  Group 2: 1 nutritional supplement a day on request&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation and benefits. This&#xD;
      study aims to tailor pulmonary rehabilitation. Participants of group 1 are visiting their&#xD;
      rehabilitation centre 3 times for study related measurements within 15 months (2 times&#xD;
      feedback on physical activity, 1 measurement visit). Participants of group 2 will be asked to&#xD;
      visit their rehabilitation centre for 6 times (1 measurement visit, 3 times nutritional&#xD;
      counseling, 1 time for feedback on physical activity, 1 time for nutritional counseling and&#xD;
      feedback on physical activity combined) within 15 months. For both groups baseline&#xD;
      measurements and outcome measurements after rehabilitation are already included in the CIRO&#xD;
      rehabilitation programme.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle strength</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Skeletal muscle strength assessed by isokinetic dynamometry (BiodexÂ®)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk profile</measure>
    <time_frame>0, 4, 12 months</time_frame>
    <description>lipid profile (blood)&#xD;
systemic inflammatory profile (blood)&#xD;
blood pressure(hematometer)&#xD;
HOMA index (blood)&#xD;
visceral fat mass (DEXA)&#xD;
AGEs skin (AGE reader)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>0, 4, 12, 15 months</time_frame>
    <description>Assessed by:&#xD;
SGRQ: Saint George Respiratory Questionnaire&#xD;
SF36: Short Form - 36&#xD;
EQ5D: EuroQol 5 domains, extended with energy/fatique domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>0, 4, 12, 15 months</time_frame>
    <description>Assessed by:&#xD;
-MRC-index: Medical Research Council dyspnoea scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>0, 4, 12 months</time_frame>
    <description>Assessed by&#xD;
- DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>0, 4, 12 months</time_frame>
    <description>Assessed by:&#xD;
- Constant Work Rate Test (CWRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of supplemented (micro)nutrients</measure>
    <time_frame>0, 4, 12 months</time_frame>
    <description>Assessed by:&#xD;
Plasma amino acids (leucine)&#xD;
Vitamin D (plasma calcidiol 25(OH)D )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mass density</measure>
    <time_frame>0, 4, 12 months</time_frame>
    <description>Assessed by:&#xD;
- DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>0, 4, 12, 15 months</time_frame>
    <description>Assessed by:&#xD;
- Accelerometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Group 1 (placebo control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (nutritional intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary supplementation</intervention_name>
    <description>Phase A, Rehabilitation (4 months): 3 nutritional supplements daily&#xD;
Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)&#xD;
Phase C, Follow-up (3 months): no supplementation</description>
    <arm_group_label>Group 2 (nutritional intervention)</arm_group_label>
    <other_name>Nutritional supplementation</other_name>
    <other_name>Dietary supplement</other_name>
    <other_name>Nutritional supplement</other_name>
    <other_name>Food supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplement</intervention_name>
    <description>Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily&#xD;
Phase B, Maintenance (8 months): No supplementation&#xD;
Phase C, Follow-up (3 months): No supplementation</description>
    <arm_group_label>Group 1 (placebo control)</arm_group_label>
    <other_name>Non-active supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional counselling</intervention_name>
    <description>Phase A, Rehabilitation (4 months): No counselling&#xD;
Phase B, Maintenance (8 months): Nutritional counselling (4x)&#xD;
Phase C, Follow-up (3 months): No counselling&#xD;
Aim:&#xD;
Optimising dietary intake to physical activity pattern and energy expenditure.&#xD;
Minimize deterioration of dietary intake during acute exacerbations.&#xD;
Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.&#xD;
Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle.</description>
    <arm_group_label>Group 2 (nutritional intervention)</arm_group_label>
    <other_name>Counselling</other_name>
    <other_name>Motivational interviewing</other_name>
    <other_name>Increasing self-regulation skills</other_name>
    <other_name>Increasing perceived competence and autonomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Feedback on physical activity level</intervention_name>
    <description>Phase A, Rehabilitation (4 months): No exercise counselling&#xD;
Phase B, Maintenance (8 months): Exercise counselling (2x)&#xD;
Phase C, Follow-up (3 months): No exercise counselling&#xD;
Aim:&#xD;
Integration of exercise behaviour into daily routine&#xD;
Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)&#xD;
Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle</description>
    <arm_group_label>Group 1 (placebo control)</arm_group_label>
    <arm_group_label>Group 2 (nutritional intervention)</arm_group_label>
    <other_name>Exercise</other_name>
    <other_name>Accelerometry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary Disease&#xD;
&#xD;
          -  Muscle atrophy (a FFMI under the sex- and age-specific 25th percentile FFMI values,&#xD;
             assessed by DEXA)&#xD;
&#xD;
          -  Eligible for pulmonary rehabilitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COPD patients under the age of 18;&#xD;
&#xD;
          -  Allergy or intolerance to fish, milk or other components of the study product;&#xD;
&#xD;
          -  Investigator's uncertainty about the willingness or ability of the patient to comply&#xD;
             with the protocol requirements;&#xD;
&#xD;
          -  Not able to stop current supplement use or if total use will be above safe upper&#xD;
             limits;&#xD;
&#xD;
          -  Participation in any other study involving investigational or marketed products&#xD;
             concomitantly or within two weeks prior to entry into the study;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Life threatening diseases like tuberculosis, carcinoma, AIDS (including HIV+), acute&#xD;
             leukaemia etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annemie Schols, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht UMC+ / NUTRIM, Respiratory Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maureen Rutten, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Centre, Institute for Medical Technology Assessment</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emiel FM Wouters, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC+ and CIRO, Respiratory Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIRO</name>
      <address>
        <city>Horn</city>
        <state>Limburg</state>
        <zip>6085 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>Muscular Atrophy</keyword>
  <keyword>Nutritional rehabilitation</keyword>
  <keyword>Counselling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

